Vaccine effectiveness of BNT162b2 mRNA Covid-19 Vaccine in Children below 5 Years in German Primary Care

Main

Despite the approval of BNT162b2 mRNA vaccine (Pfizer/BioNTech vaccine Comirnaty®) for children aged 6 months to 4 years by the European Medicines Agency (EMA) and the Federal Drug Administration (FDA) in 2022, no data on vaccine effectiveness (VE) of BNT162b2 are available in this age group. We have retrospectively described the safety of BNT162b2 (Pfizer/BioNTech vaccine Comirnaty®) administered off-label in children younger than 5 in years Germany (1). Using data from this authentication-based retrospective survey data obtained between April 14^th 2022 and May 9^th 2022 (1), we here report VE of BNT162b2 during an Omicron BA.1-2 dominant period.

We analyzed 4615 children aged 2.8±1.2 years (mean ±standard deviation) who received their first dose of BNT162b2 on January 1^st 2022 or thereafter (Table S1). We used Cox regression to estimate relative VE of two BNT162b2 doses as indicated in the Supplementary Appendix, with the period between first and second vaccine dose as reference period (24.8±0.6 days) and ≥7 days after Dose 2 to before Dose 3 as Post-vaccination period (59.5±23.6 days).

Table 1 shows that VE was substantial for SARS-CoV-2 infections, symptomatic SARS-CoV-2 infections, and SARS-CoV-2 infections leading to medication use. Differences in dosage of BNT162b2 yielded no change in VE. A sensitivity analysis assessed the geographic differences in VE (Table S2).

The present analysis showed that in comparison to one dose of BNT162b2 alone, children receiving a second dose of BNT162b2 had a substantially lower risk for being diagnosed with a SARS-CoV-2 infection or experiencing a SARS-CoV-2 infection leading to symptoms or medication use. The current data contain some limitations. First, children are rarely tested for SARS-CoV-2 and often do not seek medical attention for SARS-CoV-2 symptoms. However, this study coincided with a time when mandatory school/institution testing for SARS-CoV-2 was common in Germany. Next, the assessed vaccination strategy of BNT162b2 was not the one approved by EMA and FDA, with two instead of three BNT162b2 but higher dosages than 3μg in most participants. Furthermore, the reported VE does not necessarily correspond to the currently circulating SARS-CoV-2 variants. Finally, the present data are retrospective and await confirmation by prospective and randomized studies. In conclusion, this study offers a first industry-independent insight in the potential VE of the BNT162b2 vaccine in children aged below 5 years at a time when only immunogenicity data by the manufacturer Pfizer/BioNTech are available (2).